Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)

Inclusion Criteria: * Body weight \>=45 kg * Can be treated by taking tablet orally or intravenous (IV) formulation via central vein * Female has a negative pregnancy test * Female of non-childbearing potential; or if of childbearing potential, agrees to use proper combination of barrier method of birth control * Met screening criteria for either Invasive aspergillosis, chronic pulmonary aspergillosis, zygomycosis or fusariosis. Exclusion Criteria: * Has a fungal infection other than Aspergillus any species (spp.) Zygomycetes (including Mucor spp.) and Fusarium spp. infection * Has allergic bronchopulmonary aspergillosis, allergic sinusitis of aspergillosis, or aspergillosis of the eye * Has long-term inactive aspergilloma not expected to respond to investigational product * Is not expected to survive study duration * Has an underlying disease, complication and systemic condition which makes it difficult to evaluate effect of study drug * Has received, or continues to receive any systemic antifungal therapy, and cannot discontinue this treatment; but if fungal infection does not improve, can switch to study drug * Is expected to need prohibited medications * Has received posaconazole, has received voriconazole for this infection in the past and has deep-seated fungal infection that has not responded to this treatment, has intolerance for azole antifungal treatments, or is receiving antifungal combination therapy for chronic pulmonary aspergillosis * Has known hypersensitiv…